These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24897279)

  • 1. Cost-effectiveness of genotyping to guide treatment.
    Sorich MJ; Wiese MD; Pekarsky B
    Pharmacogenomics; 2014 Apr; 15(6):727-9. PubMed ID: 24897279
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis in pharmacogenomics.
    Payne K; Shabaruddin FH
    Pharmacogenomics; 2010 May; 11(5):643-6. PubMed ID: 20415553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?
    Bala MV; Zarkin GA
    Pharmacoeconomics; 2004; 22(8):495-8. PubMed ID: 15217306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
    Verhoef TI; Redekop WK; van Schie RM; Bayat S; Daly AK; Geitona M; Haschke-Becher E; Hughes DA; Kamali F; Levin LÅ; Manolopoulos VG; Pirmohamed M; Siebert U; Stingl JC; Wadelius M; de Boer A; Maitland-van der Zee AH;
    Pharmacogenomics; 2012 Sep; 13(12):1405-17. PubMed ID: 22966889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
    Phillips KA; Veenstra D; Van Bebber S; Sakowski J
    Pharmacogenomics; 2003 May; 4(3):231-9. PubMed ID: 12718713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
    van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
    Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the cost-effectiveness of pharmacogenomics.
    Veenstra DL; Higashi MK; Phillips KA
    AAPS PharmSci; 2000; 2(3):E29. PubMed ID: 11741245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
    Chalkidou K; Rawlins M
    Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic opportunities and challenges for pharmacogenomics.
    Deverka PA; Vernon J; McLeod HL
    Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice.
    Frueh FW
    Pharmacogenomics; 2010 May; 11(5):657-60. PubMed ID: 20415556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics: the promise of personalized medicine.
    Hood E
    Environ Health Perspect; 2003 Aug; 111(11):A581-9. PubMed ID: 12928155
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the pharmacoeconomics of pharmacogenetics.
    Dervieux T; Bala MV
    Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy.
    Phillips KA; Veenstra DL; Sadee W
    Health Serv Res; 2000 Dec; 35(5 Pt 3):128-40. PubMed ID: 16148957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.
    Olgiati P; Bajo E; Bigelli M; De Ronchi D; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):147-54. PubMed ID: 21911028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array.
    Johnson JA; Burkley BM; Langaee TY; Clare-Salzler MJ; Klein TE; Altman RB
    Clin Pharmacol Ther; 2012 Oct; 92(4):437-9. PubMed ID: 22910441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and cost-effective SNP detection method: application of SmartAmp2 to pharmacogenomics research.
    Mitani Y; Lezhava A; Sakurai A; Horikawa A; Nagakura M; Hayashizaki Y; Ishikawa T
    Pharmacogenomics; 2009 Jul; 10(7):1187-97. PubMed ID: 19604094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic criteria for covering medical interventions by the German Public Health Insurance].
    Grell L
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():18-20. PubMed ID: 10941249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of genotyping methods and the relative cost of pharmacogenomics.
    De Monaco A; Berretta M; Pugliese S; Valente D; Ciaffarafa S; Di Francia R
    Eur Rev Med Pharmacol Sci; 2014; 18(14):2084-7. PubMed ID: 25027351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.